Spiro-lactam NMDA receptor modulators and uses thereof

A compound represented by:

• or a pharmaceutically acceptable salt and/or a stereoisomer thereof, wherein:
• X is O or NR2;
• R1 is selected from the group consisting of H, C1-C6alkyl, phenyl, —C(O)—C1-C6alkyl, and —C(O)—O—C1-C6 alkyl;
• R2 is selected from the group consisting of H, C1-C6alkyl, phenyl, —C(O)—C1-C6alkyl, and —C(O)—O—C1-C6 alkyl;
• p is 2;
• R5 is independently selected for each occurrence from the group consisting of H, C1-C6alkyl, —S(O)w—C1-C3alkyl, —NRaRb, C1-C3alkoxy, cyano and halogen;
• w is 0, 1, or 2;
• R3 is selected from the group consisting of H, C1-C6 alkyl, phenyl, —C(O)R31 and —C(O)OR32;
• R31 and R32 are each independently selected from the group consisting of H, C1-C6alkyl, —C3-C6cycloalkyl, and phenyl;
• and
• R7 is independently selected for each occurrence from the group consisting of H, halogen, and phenyl;
• and
• Ra and Rb are each independently for each occurrence selected from the group consisting of H, C1-C3alkyl, and phenyl, or Ra and Rb taken together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring;
• wherein any aforementioned C1-C6 alkyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from —C(O)NRaRb, —NRaRb, hydroxyl, S(O)w—C1-C3alkyl, SH, phenyl and halogen, and any aforementioned phenyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from hydroxyl, halogen, —C(O)—O—C1-C3alkyl, —C(O)—C1-C3alkyl, methyl, and CF3.